Generate:Biomedicines Advances Anti-TSLP Antibody GB-0895 to Phase III for Severe Asthma, Plans Direct Phase III in COPD
核心洞察
Generate:Biomedicines (搜索)' lead program GB-0895, an anti-TSLP (搜索) antibody, has entered phase III trials for severe asthma (搜索) targeting biannual dosing and a 55% reduction in exacerbations across all eosinophil levels.
Phase I data supported direct advancement to phase III, showing strong biomarker modulation and comparable or superior target occupancy to tezepelumab.
The company plans to propose a direct phase III trial in COPD (搜索), potentially saving two years and significant development costs, with regulatory alignment expected soon.
Generate:Biomedicines (搜索) has advanced its lead therapeutic candidate GB-0895, an anti-TSLP (搜索) monoclonal antibody, into phase III clinical development for severe asthma (搜索), the company disclosed during the Goldman Sachs 47th Annual Global Healthcare Conference. The program, which targets thymic stromal lymphopoietin (TSLP), aims to achieve biannual dosing and a 55% reduction in asthma exacerbations across all eosinophil (EOS) levels, positioning it as a potentially differentiated contender in the biologic asthma market.
The phase III initiation follows phase I data that demonstrated sufficient promise to bypass phase II entirely. According to the company's presentation, the early-stage results showed strong biomarker modulation and target occupancy that was comparable or superior to tezepelumab (Amgen/AstraZeneca's TSLP (搜索)-targeting antibody, marketed as Tezspire). This direct advancement underscores the efficiency of Generate:Biomedicines (搜索)' integrated discovery platform.
COPD (搜索) Program Eyes Accelerated Path
Beyond asthma, Generate:Biomedicines (搜索) is preparing to propose a direct phase III trial of GB-0895 in chronic obstructive pulmonary disease (COPD (搜索)). The company indicated that this accelerated development strategy could save approximately two years and significant costs compared to a traditional phased approach. Regulatory alignment discussions are expected to conclude soon, marking a critical milestone for expanding the antibody's therapeutic footprint into a disease area with substantial unmet need.
Platform Capabilities and Pipeline Expansion
Generate:Biomedicines (搜索)' progress rests on a tightly integrated dry and wet lab infrastructure that combines computational protein design with high-throughput experimental validation. The company operates four cryo-electron microscopy (cryo-EM) microscopes, solving protein structures at atomistic resolution on a daily basis. This feedback loop, the company argues, refines protein design beyond what traditional immunization or biophysical methods can achieve.
The platform is modality-agnostic, with active work spanning eight modalities and a focus on large molecules. Key differentiators include the ability to achieve atomistic resolution in protein-protein interactions and the rapid generation of experimental data to continuously train predictive models.
In oncology, the pipeline includes a payload neutralizer designed to mitigate peripheral neuropathy associated with MMAE-based antibody-drug conjugates (ADCs). A phase I dose-escalation study is underway, with data expected by 2027. Additionally, a CAR T program targeting MUC16 (搜索) in ovarian cancer (搜索) is entering the clinic, leveraging the company's technology to optimize binding and framework design specifically for solid tumor applications.
Partnership Strategy
Generate:Biomedicines (搜索)' existing collaborations with Amgen and Novartis are reportedly nearing completion, and the company signaled that new partnerships are expected within the next 6 to 18 months. These alliances complement the internal pipeline and validate the platform's capacity to generate novel protein therapeutics across diverse target classes and disease areas.